These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38692939)

  • 1. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
    Wang J; Li J; Zhong L
    Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
    Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
    Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
    J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis.
    Sizova DV; Raiker S; Lakheram D; Rao V; Proffitt A; Jmeian Y; Voegtli W; Batonick M
    Biochem Biophys Rep; 2023 Jul; 34():101442. PubMed ID: 36875796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
    Morgan GJ; Wall JS
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.
    Quarta CC; Fontana M; Damy T; Catini J; Simoneau D; Mercuri M; Garcia-Pavia P; Maurer MS; Palladini G
    Front Cardiovasc Med; 2022; 9():1073503. PubMed ID: 36606280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for cardiac light chain amyloidosis: An update.
    Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
    Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
    Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
    Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods to study the structure of misfolded protein states in systemic amyloidosis.
    Fändrich M; Schmidt M
    Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
    Wong SW; Fogaren T
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.